The utility of a size exclusion high-performance liquid chromatography (SE-HPLC) method, in the identification and quantitation of haemagglutinin (HA) protein in monovalent, inactivated influenza vaccines for the purposes of potency assessment is reported. This method is sufficiently developed to provide a distinct peak separation of HA from other vaccine constituents, and a correlation with HA potency determined by single radial-immunodiffusion (SRID) assay. Sensitivity of the method is demonstrated, with each HA peak accurately titrated to the HA content of the protein load injected. Highly reproducible chromatographic profiles (on a G4000SWxl column) were achieved, demonstrating vaccine protein integrity and stability. Potency assessments, determined by SE-HPLC peak area analysis, provided very good correlation with the quantitative HA protein values, determined by SRID, reported by the manufacturer and by Health Canada's Centre for Biologics Evaluation, Pandemic Influenza Division (PID). Peak resolution was further enhanced by expanding to a tandem SE-HPLC system, utilizing a G4000SWxl SE column coupled to a G3000SWxl column. HA was detected in the 11-17 minute (min) elution, collected in 30 second (sec) fractions, with the smallest, most distinct peak width detected to date at the 15.5 min fraction. This SE-HPLC method has considerable potential for widespread use as a physicochemical method for HA identification and quantification, in quality control testing for seasonal and pandemic influenza vaccines, and as a practical alternative for potency measures by the reagentdependent SRID assay. Increased resolution and further method development will facilitate the collection of separated fractions for further analysis, to correlate immunoactivity to HA type and content.
he influenza virus is a contagious disease of animals and is categorized as a genus of the family Orthomyxoviridae. Influenza viruses are classified according to antigenic differences in their nucleoprotein (NP) and matrix protein (MP1), creating types A, B, and C, 3 with solely type A strains being associated with pandemics. 1 Type A influenza viruses are further subdivided based on antigenic differences in their main surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA). These major surface antigens are the targets of the host immune response, despite the fact that they are subject to rapid and unpredictable antigenic variation. 2 Albeit the natural reservoir for all influenza viruses is aquatic birds 6 , types A and B influenza viruses have been found in human isolates during the past decade, and have been responsible for numerous outbreaks around the world 3 . Of concern is subtype H5N1 due to its ability to cross the species barrier over to humans. There has been a notable increase in the direct transmission of the H5N1 avian influenza virus to humans 6 . As of December 18 2007, the emerging H5N1 virus has infected 340 individuals since 2003, causing 209 deaths in 13 countries (a 61.5% mortality rate). 8 With the added possibility of mutation and genetic reassortment that could lead to human-to-human transmission, H5N1 is a strong candidate for a potential influenza pandemic.
Continued surveillance is indispensable to pandemic preparedness plans. The World Health Organization Influenza Surveillance Programme along with other national health authorities, have been able to make recommendations on vaccine composition. 10 To date, vaccines are the main medical intervention for protecting individuals from influenza outbreaks. 9 In light of an impending pandemic, drug manufacturers are seeking to develop prototype avian/pandemic influenza vaccines.
As a regulatory agency, Health Canada is directly responsible for the assessment of potency, safety and purity of prototype pandemic influenza vaccines. Potency of influenza vaccines is currently determined on the basis of the vaccine HA content and its ability to generate an effective immune response (against the antigen.) The principle underlying the mechanism of action for influenza viruses is the induction of protective antibodies that guard against the HA glycoprotein of the predicted epidemic strain. 6 
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Vol. 1, No. 2, Winter 2008, 7-19 At present the SRID method, approved by the European Pharmacopoeia Commission for the evaluation of inactivated influenza vaccines 5 and used by most regulatory agencies worldwide, is the only method which provides a visual, easily detectable measure of antigen/antibody binding as a measure of potency. A value of 15 µg of HA per strain per dose is used for vaccination. 3 The SRID assay requires a reference antigen reagent to be used as a calibrator and specific antibodies against this antigen. 3 The interaction of antigen and antibody creates a zone of precipitation in a semi-solid medium, the diameters of which can be directly correlated to the amount of HA present. 5 The SRID method is very specific and requires little technology; SRID reagents take approximately 2-3 months to produce-which would be too long in the case of a pandemic outbreak. In an emergency situation, alternative estimates of vaccine potency before reagents become available would be of critical importance. It would therefore be valuable to accumulate comparative data between the SRID test and alternative physicochemical techniques, in order to validate more unconventional approaches towards potency testing. 11 Among them are high resolution chromatographic techniques.
A relatively recent publication has explored twodimensional high-performance liquid chromatography (2D-HPLC), coupling size exclusion HPLC with reverse phase HPLC, to characterize influenza vaccine constituents. 3 The assessment found that vaccines made by different manufacturers had significantly different profiles, while different vaccine lots within the same manufacturer demonstrated consistent results. This research is of particular interest to pandemic preparedness strategies due to the fact that HA, along with some other viral proteins, was found to separate into a particular peak on the chromatograms. The amount of HA found in the peak correlated fairly well with the amount of HA in the original vaccine preparation.
The Pandemic Influenza Division has adapted methods used by García-Cañas et al., 2007, in the part of physicochemical methods for the characterization and measurement of potency of the pandemic flu vaccines. A novel procedure, requiring no sample pre-treatment, through two size exclusion columns in series was developed. The potential of this SE-HPLC system to quantitate HA was determined with comparative methods such as SRID and protein assays.
MATERIALS AND METHODS
Chemicals
All chemicals were of analytical reagent grade and used as received. Sodium chloride crystals were from EMD, Dithiothreitol (DTT) solution and sodium dodecyl sulphate (SDS) were from Sigma Aldrich, and sodium phosphate dibasic anhydrous was from Fisher. Seakem™ ME Agarose was obtained from Cambrex, Zwittergent ™ 3-14 Detergent was from Calbiochem, and D-PBS was purchased from Wisent. Coomassie® Brilliant Blue G-250 was purchased from Bio-Rad, and acetic acid and methanol were from OmniSolv. Micro BCA™ Protein Assay Kit was purchased from Pierce. Distilled water was purified with Milli-Q Synthesis System. 
Samples
Separation Conditions
The samples were stored at 4°C prior to use. Once aliquoted into HPLC vials, samples were placed in a temperaturecontrolled autosampler tray set at 15°C. The analytical chromatographic columns used in this investigation were the following: Tosoh TSK G4000SWxl, pore size 450Å, 7.8mm (ID) x 30cm (L), Tosoh TSK G3000SWxl., pore size 250Å, 7.8mm (ID) x 30cm (L), Tosoh TSK G2000SWxl, pore size 125Å, 7.8mm (ID) x 30cm (L), and Tosoh TSK G3000SW, pore size 250Å, 7.5mm (ID) x 60cm (L). Performance qualification of columns was assured by standard SE chromatograms of the following samples: Thyroglobulin (Thermo), Ferritin (Sigma), Ovalbumin (Sigma), γ-globulin (Sigma), p-Aminobenzoic acid FW 137.14 (Sigma). Separation was carried out at room temperature. The mobile phase was isocratic and consisted of the following: 0.1M Na 2 HPO 4 , 0.2M NaCl, 0.1% SDS, and was adjusted to pH 7 with 4N NaOH (Sigma), except when samples were tested at pH 5. Elution was carried out at a flow rate of 1.0 mL/min. Detection wavelength was set at 214nm.
Protein Analysis
MicroBCA (bicinchoninic acids) protein assay kit was used (Pierce). The absorbance of the samples, standards of bovine serum albumin (BSA), and controls (sample diluent, PBS) was measured at 562nm on a Multiskan Spectrum spectrophotometer (Thermo). Total protein was quantified as BSA equivalents, based on a standard curve of 0, 0.5, 1, 2.5, 5, 10, 20, 40, 200 µg/mL of BSA. This method uses BCA as the detection reagent for Cu +1 , which is formed when Cu +2 is reduced by protein in an alkaline environment. It was chosen for its compatibility with the samples, as well as a working range of 2-40µg/mL available as a microplate procedure, which permitted all samples to be read simultaneously. Results were analysed by the SkanIt Software 2.2, and compiled in Microsoft Excel (XP).
RESULTS AND INTERPRETATIONS
The initial set of experiments investigated any correlation of HA content in the sample vaccine with peaks obtained by SE-HPLC.
SRID
At present, SRID is the established analytical method for the measurement of HA content in vaccines. Table 1 illustrates SRID results for 10 monovalent lots (Vaccines A-J) from 2004.
SE-HPLC Selectivity
Initial steps utilized SE-HPLC to determine if the components of the vaccine could be reproducibly separated and if any of the peaks correlated with the HA content of the vaccine. The applicability of the SE-HPLC setup was first assessed using several relational assessments. SE-HPLC's ability to produce chromatograms in which each peak could be accurately titrated to the HA content of the sample is demonstrated in Figure 1 (the load responsiveness of the system). Peaks are labelled 1-8 and the designated putative HA peak is Peak 3 (see Figure 1) . The assay linearity was determined by plotting the putative HA peak area, having a retention time (RT) of approximately 9 min. (25µL injection RT: 9.033), as function of the amount of sample (µL) injected (Figure 2) . The standard curve illustrated in Figure  2 shows that peak area is proportional to the amount of HA injected into the SE-HPLC system. Adequate linearity was demonstrated by a correlation coefficient of > 0.99.
The applicability of the SE-HPLC setup for HA quantification was further assessed. Several standard curves were taken from various peaks of sample K chromatographic profile to calculate the amount of HA present in the SE-HPLC injection. These values were then compared with the manufacturer's Certificate of Analysis (CoA) ( Tables 2 to  5 ). This suggests that SE-HPLC is distinct enough to be used for peak separation and potency assessment, irrespective of the location of the putative HA peak. The data suggests that each peak can be accurately titrated to the HA content of the protein load injected, appearing in Figures 3 to 6. Sample K was used for each injection on the G4000SWxl column. 
Year
SE-HPLC Reproducibility
Replicate injections of sample K were performed on different days and peak areas were compared, and the mean and the standard deviation among injections were calculated. Results are expressed in Table 6 and a qualitative representation of the data is presented in Figure 7 . Figure 7 suggests that peak areas may be used to determine potency measures and are consistent and highly reproducible. Other consistent patterns have been obtained for two 2005 New York strains as well as for two 2005 Jiangsu strains. This suggests that the SE-HPLC is likely to be applicable to different influenza strains, irrespective of their variations in HA, and may be utilized for a predicted H5N1 pandemic strain. Table 7 . This slight decline in potency may be attributed to many factors such as the possibility of degradation over time as well as aggregation of the proteins which occurs upon storage of any vaccine.
Sample Stability and Manufacturing Consistency
Another point of interest lies in the manufacturing consistency. The HA content of the monovalent bulks produced in 2004, by SRID determination, varied from 411 to 748 µ g/ml, while the HA content of 3 lots of the same Table 7) . This amount of variation in HA content among lots of monovalent bulks is quite typical of biological systems.
In contrast, the SE-HPLC profile is quite consistent among all lots tested, and the respective content correlations demonstrate less variability. 
Correlation between SE-HPLC and SRID
Potency measure by HA titres of influenza monovalent bulks, as determined by SE-HPLC and those obtained by the established SRID method were studied and compared to the v a l u e s p r e s e n t e d i n t h e m a n u f a c t u r e r ' s C o A. H A concentration can be estimated by SE-HPLC using the following calculation concept: As previously mentioned, SRID is the established method for HA content determination, ie. potency testing, and was the confirmatory method for HA quantification. Thus, the above gross calculation of HA content using SE-HPLC should also be comparable to SRID results. As shown in Table 8 , the HPLC data on average gave potency values ~106% of those supplied by the manufacturer on the CoA, and ~119% of the SRID potency results. These data show that there is relatively good correlation between results obtained for the determination of HA content, by SRID and HPLC methods. Interestingly, the SRID data (derived from the CoA testing, at production), and the HPLC results were in closer agreement than comparisons made at times post-manufacture, for consistency testing. It is not yet clear in the studies if the HPLC method is unable to separate any degradation products, which may compromise HA content calculations.
This calculation concept has also been proven for 2005 monovalent lots of vaccine K, with data provided by Dr. Cynthia Allen, PID, CBE, BGTD, Health Canada, Feb.14, 2007.
The MicroBCA protein assay was used as a confirmatory method for the quantification of total protein content of the monovalent bulks and the results appear in Table 9 . On average, there appears to be a systemic increase in the MicroBCA results, as compared to those provided by the manufacturer (Figure 9) . However, this is a sufficiently reasonable trend for several reasons. The samples are 3 years old and are subject to degradation and aggregation in addition to the lack in consistent homogeneity in many biological substances such as vaccines. Of greater importance is the fact that the manufacturer used a different analytical method, Kjeldahl nitrogen analysis. 7 Whereas the BCA assay measures the number of peptide bonds accessible to the colour reagent, the Kjeldahl method quantifies the total nitrogen of both proteinaceous and non-proteinaceous compounds. It is known that interefering substances can influence the results obtained by the MicroBCA method and these are suspected causes of increased total protein values.
Optimization methods PID's current approach to quantifying HA using SE-HPLC has proven feasible. However, current efforts are focused on the ability to improve HA peak resolution on the SE-HPLC system since the G4000SWxl column yielded an insufficiently resolved HA peak, making it difficult for future quantification that would require isolation and collection of the HA peak. Several variables were assessed including: mesh size of the column beads; connecting several SE-HPLC columns together in series (tandem SE-HPLC), and alterations in the temperature and pH of the elution buffer to try to induce conformational changes in the HA molecule. Table 10 illustrates the various manipulations made in order to optimize HA peak resolution. The most significant of these manipulations were the changes in column pore size as well as the use of two-dimension SE chromatography (using two columns in series). Figures 10 and 11 are included to illustrate the differences in sample chromatographic profiles run on different columns. The data suggests that by changing separation conditions, such as column resolution range, HA (which has a molecular mass of ~83kDa when uncleaved 4 and in its monomeric form) elutes at different times and for different durations during a run. This was directly confirmed by collecting fractions from the sample injections and confirming the presence of HA in the alleged HA peaks using SRID.
The putative HA peak retention times for column G4000SWxl, G2000SWxl, G3000SWxl, and G4000SWxl-G3000SWxl are 9.17min, 6.37min, 6.36min, and 15.32min, respectively. Columns G4000SWxl-G3000SWxl in series were evaluated as being the optimal SE-HPLC setup, taking into account location of putative HA peak, width of HA peak, and chromatographic profile.
G4000SWxl's putative HA peak resolution was poor and contained an unresolved shoulder peak, as seen in Figure  10(a) . In addition, the width of the peak was very wide as proven by SRID, which contained detectable amounts of HA in fractions eluting at minutes 8, 9, and 10.
Column G2000SWxl demonstrated a more narrow HA peak width (with a SRID detection from minutes 5 and 6), however its retention time of 6.36min was far too close to the elution of high molecular mass components, due to its proximity to the first spike on the chromatographic profile in Figure 10(b) . This suggests the possibility of contaminating proteins in the putative HA peak. It appears that neither of 
Optimization Methods
Various combinations of Methods
Columns: ----------------------------2-D HPLC --------------------------
• TSK G3000SWxl, pore size 250Å
• TSK G2000SWxl, pore size 125Å X X (2 nd )
• 60cm G3000SWxl, pore size 250Å X Mobile phase properties:
• treat with DTT, 26°C these columns were optimal for identifying and isolating the putative HA peak. Based upon the above analysis, the G3000SWxl is expected to yield more optimal results since HA should elute between the previous two retention times. Figure 10(c) demonstrates that the HA peak is better resolved than in the G2000SWxl column. However HA was detected in quite a vast range by SRID, eluting from minutes 4.5-7. In addition, its retention time of 6.37 is unexpectedly low and near that of the G2000SWxl column. It appears that the G3000SWxl gives a pattern that is not easily correlated to those of the G2000SWxl and G4000SWxl. It is speculated that this may be related to secondary interactions that may play a greater role with this particular type of column.
This led to the use of two columns in series, as modeled in Figure 11 . The use of tandem HPLC was suspected to separate out the HA peak even further. The first column would perform an initial separation, and the second column would further isolate the sorted vaccine sample constituents. SRID results detected HA in minutes 15.5, suggesting the putative HA peak width is the smallest detected to date, and correlates well with the chromatogram retention time of 15.32min. The inversion of columns G4000SWxl and G3000SWxl in series yielded only minimal differences. Figure 11(b) illustrates a slightly enhanced resolution immediately prior to the elution of HA at 15.32min, suggesting that some contaminating proteins from the HA peak have been further separated out, thus facilitating HA identification, isolation, and ultimately quantification.
Recommendations and Future Prospects
The use of a tandem SE-HPLC method, along with the conventional SRID method to quantitate HA has proven effective in identifying the peak containing HA, and in correlating HA content determined by SE-HPLC with SRID potency results. Now that this correlation has been established, more data must be assessed to further validate the method for HA quantification. Of importance will be its ability to assess samples of H5N1, or other identified strains of prototype vaccine lots, for the identification and quantification of HA for a potential pandemic strain. However, in order to estimate the precise amount of HA as a potency measure, sufficient for regulatory purposes, a standard HA preparation (which is unlikely), or alternatively, a measure of the amount of contaminating proteins in the HA peak is required. This will have implications for the actual pandemic vaccine since the amount of contaminating proteins will be unknown. It therefore remains to be investigated whether the ratio of HA: contaminating protein in the peak can be estimated by the use of other separation techniques.
Reverse-phase HPLC (RP-HPLC) for this application has already been explored by Kapteyn in 2006 , and more recently by Garcia-Cañas and collegues. Garcia-Cañas et al. were able to separate HA from other viral proteins into a single peak with good reproducibility, but were limited by their ability to quantitate the amount of HA present. Although Kapteyn et al. successfully quantified HA, samples tested were not formaldehyde treated. Considering that eggbased influenza vaccines are routinely inactivated with formaldehyde (which introduces irreversible cross-linking of the HA subunits in their manufacturing process), such an analytical method is not directly approved. However, along the line of the Garcia-Cañas et al. study, it appears that RP-HPLC may be used to identify contaminating proteins of the HA peak. To date, preliminary work has began to investigate the applicability of RP-HPLC to identify the amount of coeluting proteins in the HA peak.
Capillary electrophoresis (CE) is another physicochemical technique that may be used for contaminating protein identification. Its main advantage over HPLC is its minimal sample preparation time and small amounts of sample and solutions required, making it a competitor for the quick assessment of sample contents, including molecular weight, aggregates, and modified forms of the protein samples. The development of alternative physicochemical methods is imperative for the preparation of an upcoming pandemic and SE-HPLC's ability to identify and potentially quantitate influenza vaccine potency may serve as an invaluable tool to pandemic preparedness strategies.
